Anti-Neprilysin Market - Size, Share, Outlook, and Opportunity Analysis, 2019

Anti-neprilysin drugs are majorly used for acute heart failure, cancer pain, hypertension, Alzheimer’s disease, and other diseases. Most commonly used anti-neprilysin is Sacubitril/valsartan, which is sold under the brand name, Entrest. It consists of neprilysin inhibitor, sacubitril and the angiotensin receptor blocker, valsartan. Entrest was first manufactured by Novartis International AG in 2015. After the arrival of this drug in the market, there has been a reduction in the rate of cardiovascular deaths and hospitalization related to heart failure. Due to the increasing prevalence of heart failure, the U.S.FDA granted fast track designation to Entresto in 2015, which supports FDA’s efforts to facilitate the development and expedite the review of drugs to treat serious or life-threatening conditions and meet unmet medical needs of patients.

Market Dynamics

The increasing prevalence of acute heart failure is expected to highly contribute to the anti-neprilysin market growth over the forecast period. For instance, according to the data published in the Continuing Cardiology Education Journal in 2017, heart failure (HF) is a major public health problem, affecting a total of 26 million people worldwide in 2014. Furthermore, according to the American Heart Association report, the prevalence of acute heart failure in the U.S. in 2012 was 5.7 million, representing 2.2% of the population. The projection is that HF prevalence will increase by 46% by 2030, resulting in over 8 million adults with HF in the U.S. in 2030.

However, the anti-neprilysin market growth is expected to be hampered over the forecast period, owing to the side effects and adverse effects associated with anti-neprilysin drugs. For instance, the drug called Entresto (sacubitril and valsartan), a combination of a neprilysin inhibitor and an angiotensin II receptor blocker, might exhibit serious side effects such as low blood pressure (hypotension), high blood potassium (hyperkalemia), cough, dizziness, and kidney (renal) failure. Such side effects can create life-threating conditions if not consumed under expert supervision.

Key features of the study:

This report provides in-depth analysis of the global anti-neprilysin market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global anti-neprilysin market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Bioprojet SCR, Novartis International AG, Pharmaleads SA, Theravance Biopharma Inc., Cipla Limited, and Oceanic Pharmachem Pvt. Ltd.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global anti-neprilysin market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for anti-neprilysin market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

Global Anti-Neprilysin Market, By Drug Type: